Wednesday, May 04, 2022 OVC1- Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, varez Secord A, Moxley KM, Bookman MA. (ONLINE). J Clin Oncol 2022. https://ascopubs.org/doi/abs/10.1200/JCO.21.02011?cid=DM10017&bid=152282035 CEC1 - Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. van den Bent MJ, Tesileanu CM, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. The Lancet Oncology 22: 813-23, 2021. https://www.sciencedirect.com/science/article/pii/S1470204521000905 General Statistical Publication Wei K, Zhu H, Qin G, Zhu Z, Tu D. Multiply robust subgroup analysis based on a single-index threshold linear marginal model for longitudinal data with dropouts (ONLINE). Statist Med 2022. https://onlinelibrary.wiley.com/doi/full/10.1002/sim.9386
